Olpress

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Olpress

Quick Facts

Property Description
Active Ingredient Olmesartan Medoxomil
Active Moiety Olmesartan
Form Film-coated tablet
Pharmacological Class Angiotensin II Receptor Blocker (ARB)
General Purpose To lower high blood pressure
Origin / Type Synthetic prodrug, Prescription-only medicine (Rx)

Defining Olpress: Classification and Composition

Olpress is a prescription-only medicine containing the active ingredient Olmesartan Medoxomil. This compound is classified as a synthetic prodrug that belongs to the group of agents known as Angiotensin II Receptor Blockers (ARBs). The medication is presented as a film-coated tablet designed for oral administration, allowing for systemic action throughout the body.

As a prodrug, Olmesartan Medoxomil is chemically inert upon ingestion but is rapidly converted during absorption into its therapeutically active form, Olmesartan. This single-ingredient formulation is typically used for monotherapy in adult patients requiring regulation of vascular tension.


Mechanism and General Purpose

The general purpose of Olpress is to achieve a targeted blood pressure lowering effect by intervening in the body's pressure regulation system. Olmesartan accomplishes this by executing the selective blockade of the Angiotensin II type 1 (AT1) receptors.

By blocking these receptors, the drug prevents the hormone Angiotensin II from exerting its signals for vasoconstriction (vessel tightening). This action causes blood vessels to widen and reduces resistance to blood flow, a mechanism that provides a potent, long-lasting blockade of Angiotensin II. This efficacy underscores its role as an established agent for the sustained management of circulatory balance in patients.

What side effects are possible with Olpress?

Possible Side Effects and Safety Information

The safety profile of Olpress (olmesartan medoxomil) is documented by governmental regulatory authorities and includes adverse reactions classified by frequency, system-organ class, and severity. This information organizes the known risks of the medicine.


Safety Restrictions and Contraindications

  • Pregnancy: Use during the second and third trimesters is strictly prohibited (contraindicated) due to the risk of injury and potentially death to the developing fetus, including conditions like low blood pressure and kidney failure.
  • Drug Interaction: It is contraindicated for use with the medicine aliskiren in patients who have diabetes.
  • Pediatrics: Use is contraindicated in children younger than one year of age.

Adverse Reactions and Serious Risks

Adverse reactions are organized based on frequency observed in clinical trials and reports from post-marketing surveillance.

  • Common Reactions (ge 1%): The most frequently reported adverse reaction in adults is dizziness. Other common reactions include headache, upper respiratory tract infections, and bronchitis.
  • Serious Adverse Reactions (Post-Marketing): Rare but clinically significant reactions have been reported, including a severe, chronic diarrheal illness with significant weight loss known as sprue-like enteropathy. This condition may develop months to years after starting treatment and requires discontinuation of Olpress. Other serious risks include angioedema (swelling of the face, lips, and throat) and rare reports of autoimmune hepatitis.

Regulatory Safety Note: Patients with reduced salt or fluid volume or pre-existing severe congestive heart failure may experience excessive drops in blood pressure upon starting treatment, which requires careful monitoring.

Overdose and Emergency Response

Overdose and When to Seek Help

This information is based on official guidance from health regulatory authorities regarding Olpress (olmesartan medoxomil) overdose.


Overdose Scope

Domain Official Regulatory Statement
Documented Overdose Presentations The primary clinical consequence of overdose is an exaggerated extension of the therapeutic effect, primarily resulting in significant hypotension (low blood pressure) [NIH/MedlinePlus]. Associated symptoms listed in prescribing information include dizziness, fainting (syncope), tachycardia (fast heart rate), and bradycardia (slower heart rate) [FDA Prescribing Information].
Physiological Systems Affected The Cardiovascular system is primarily affected, leading to severe blood pressure and heart rate abnormalities [FDA Prescribing Information].
Dose-Related Factors Overdose is strictly associated with taking a quantity of the medication too much for the intended use [NIH/MedlinePlus].
Population-Specific Overdose Notes None documented specifically within the acute overdose management sections of the regulatory labels for pediatric, geriatric, or organ-impaired populations.
Emergency-Response Statements Management is symptomatic and supportive. For symptomatic hypotension, the patient should be placed in the supine position and, if necessary, administered an intravenous infusion of normal saline [FDA Prescribing Information].
When Immediate Medical Help Is Required Individuals must seek emergency medical attention immediately, or call the Poison Help line for any known or suspected overdose [NIH/MedlinePlus].

Overdose Classifications

Classification Official Regulatory Statement
Severity Classification The most severe outcome is profound hypotension, which may lead to inadequate perfusion [FDA Prescribing Information].
Antidote Status No specific antidote is known [European Public Assessment Report]. Furthermore, olmesartan is not removable by hemodialysis [European Public Assessment Report].

Connection to the Overall Overdose Profile

The regulatory profile defines the overdose situation by the critical risk of profound hypotension, which represents the most severe manifestation of the drug’s intended effect. Therefore, official guidance mandates that any suspected overdose requires immediate emergency medical attention to stabilize the patient’s vital signs. The limited supportive management described in the official documents reflects the fact that no specific antidote is known for this compound.

Therapeutic Uses of Olpress

Olpress is an authorized prescription medication medically indicated for the management of high blood pressure (hypertension) in adult patients and in pediatric patients aged 6 years and older. Effective management of this condition is a foundational component of overall cardiovascular health.

The primary therapeutic role of Olpress is to support the reduction and maintenance of blood pressure within a target range. This intervention is a key part of the comprehensive treatment plan for patients diagnosed with primary or essential hypertension. Consistent blood pressure management may help mitigate the constant strain on the heart and blood vessels throughout the body.

In clinical scenarios, the medication is prescribed to address hypertension, to support renal health in individuals with hypertension and Type 2 diabetes, and to help lower the probability of major cardiovascular events, such as stroke and myocardial infarction.

Quick Fact: Support for Blood Pressure Management

Olpress is medically indicated to support the reduction of elevated blood pressure, which assists in managing cardiovascular risk.

Eligibility and Restrictions for Use

Olpress (Olmesartan Medoxomil) is authorized for use in adult patients and pediatric patients aged 6 years and older for the treatment of hypertension. However, official regulatory labeling specifies several populations for whom use is prohibited, restricted, or not recommended.

Contraindicated Populations

Classification Population Status
Pregnancy Second and third trimesters Contraindicated
Dual Therapy Patients with Diabetes Mellitus receiving aliskiren Contraindicated
Hypersensitivity Known allergy to the active substance or excipients Contraindicated
Hepatobiliary Biliary obstruction Contraindicated

Age-Specific and Condition-Based Restrictions

  • Infants below 1 year of age must not receive Olpress due to specific safety concerns and lack of data.
  • Use in children aged 1 to 5 years is not recommended as safety and efficacy have not been established.
  • The medicine is not recommended for patients with severe renal impairment (creatinine clearance <20 mL/min) or severe hepatic impairment due to limited clinical experience.
  • Use in the first trimester of pregnancy is not recommended, and the drug should be discontinued as soon as possible if pregnancy is detected.
  • Breastfeeding is not recommended during treatment.

These official statements define the boundaries for appropriate use, classifying populations as contraindicated, not recommended, or eligible based on age, physiological state, and co-existing conditions, as documented by regulatory authorities.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Olpress (Olmesartan Medoxomil) is structured around specific official restrictions concerning pharmacodynamic effects and the drug’s absorption.

Contraindicated Combinations and Restrictions

Co-administration with Aliskiren is formally contraindicated in two specific populations: patients with Diabetes Mellitus and patients with moderate-to-severe Renal Impairment (GFR less than 60 mL/ min/1.73 m^2). The regulatory label details that dual blockade of the Renin-Angiotensin System (RAS), including with ACE inhibitors, increases risks of hypotension, hyperkalemia, and renal function changes.

Pharmacokinetic and Timing Rules

Co-administration with Colesevelam Hydrochloride reduces the systemic exposure and peak plasma concentration ( C max) of Olmesartan due to reduced absorption. To mitigate this pharmacokinetic interaction, Olpress must be administered at least 4 hours before the dose of Colesevelam Hydrochloride.

Pharmacodynamic Effects and Cautions

Co-administration with Nonsteroidal Anti-inflammatory Drugs (NSAIDs) or selective COX-2 inhibitors may result in a loss of the antihypertensive effect and an increased risk of deterioration of renal function. This renal risk is noted as being higher in elderly, volume-depleted, or renally compromised patients. Other agents that increase serum potassium, such as Potassium-sparing Diuretics or Potassium supplements, may increase the risk of hyperkalemia. Furthermore, the label notes that combining Olpress with Lithium may increase the risk of lithium toxicity, and Alcohol (Ethanol) consumption may increase the risk of dizziness.

Mechanism of Action

Olpress is a selective Angiotensin II Type 1 ( AT1) receptor antagonist. The active compound, olmesartan, functions by competitively blocking the binding of the endogenous ligand Angiotensin II to the AT1 receptors. These receptors are located on the cell surfaces of tissues critical to systemic vascular regulation, including the vascular smooth muscle and the adrenal glands. The AT1 receptor mediates the primary effects of Angiotensin II, such as cellular growth, peripheral resistance regulation, and aldosterone release. This receptor blockade prevents the downstream signaling cascade typically initiated by Angiotensin II. Consequently, vasoconstriction and aldosterone secretion are inhibited. The resulting modulation of these pathways decreases peripheral vascular resistance and promotes a reduction of plasma volume through reduced renal sodium and water reabsorption.

Dosage and Administration Information

How to Use Olpress

Olpress (Olmesartan Medoxomil) is approved for oral administration as a film-coated tablet, establishing the singular route of use for this medication. The medicine is prescribed on a once-daily schedule, which promotes consistent systemic action. The tablet may be taken with or without food, providing flexibility in daily intake timing, though taking it at the same time each day is suggested to aid adherence.

For adult monotherapy, treatment typically begins with a daily dose of 20 mg. A lower starting dose of 10 mg once daily is used in patients with moderate hepatic impairment. The dose may be adjusted after approximately two weeks of therapy, based on the patient's blood pressure response, up to the maximum labeled adult dose of 40 mg once daily.

Usage rules specify certain limitations for vulnerable populations. For patients with moderate renal impairment, the maximum daily dose should not exceed 20 mg. Dosing for pediatric patients (6 to less than 18 years) is determined by body weight, with children weighing under 35 kg having a maximum dose of 20 mg once daily, while those 35 kg and over can use up to 40 mg daily. In terms of administration, the tablet must be swallowed whole with a sufficient amount of fluid and must not be chewed. If a dose is missed, it should be taken as soon as possible, but if it is nearly time for the next scheduled dose, the missed dose is skipped to prevent doubling.

Recent Clinical Evidence

Recent Clinical Evidence: Olpress

1. Research Scope and Findings

Clinical studies have primarily focused on the use of Olpress (olmesartan) in managing chronic hypertension (high blood pressure). Research investigated whether there is a reduction in elevated blood pressure, which is linked to preventing cardiovascular events such as stroke and heart attack.

  • Studies evaluated the association of the drug's use with a reduction in both systolic and diastolic blood pressure over treatment periods, typically ranging from 6 to 12 weeks.
  • Research examined the reported changes in blood pressure over a 24-hour dosing interval, with trough-to-peak ratios reported in the 60%–80% range in specific trials.

2. Pharmacokinetic Profile and Action

Pharmacokinetic studies describe the drug’s behavior in the body. The half-life reported in clinical trials was approximately T1/2 = 10 to 15 hours, with steady-state concentrations generally reached after the first few doses.

  • The research explored the drug’s activity as an Angiotensin II Receptor Blocker (ARB), which functions by blocking the binding of Angiotensin II to its receptor (AT1).
  • In studies, the drug was administered with food to evaluate its absorption profile, noting that the drug is rapidly converted to its active form during absorption.

3. Combination Therapy Research

Studies have investigated Olpress in combination with other antihypertensive agents, such as diuretics (e.g., hydrochlorothiazide) and calcium channel blockers (e.g., amlodipine), to assess their combined effect on achieving blood pressure goals.

  • A key finding was that the combination was associated with greater blood pressure reductions compared to monotherapy, which suggests complementary mechanisms of action.
  • Research examined whether the drug is suitable for long-term use, and no evidence of rebound hypertension was reported following abrupt withdrawal in studies up to one year.

4. Special Populations and Safety Profile

Research involving the drug focused safety assessments primarily on adult patients (aged 18–65). Studies have not yet conclusively investigated the effects in pregnant or lactating individuals due to potential fetal risk associated with ARBs. Findings were mixed regarding its use in patients with severe pre-existing renal impairment, and caution was noted in the study reports due to potential accumulation of the active drug. Studies have not yet conclusively investigated its use in pediatric populations below the age of 6.

Frequently Asked Questions (FAQ)

Common questions about Olpress (FAQ)

Q: How quickly does Olpress start working after I take it?

A: Studies and official information indicate that the blood pressure-lowering effect of Olpress is often noticeable within the first 2 weeks of starting therapy. The medication usually reaches its maximal effect after approximately 8 weeks of consistent use.

Q: What's the difference between Olpress and other common blood pressure drugs?

A: Olpress is categorized as an Angiotensin II Receptor Blocker (ARB). This means it works by specifically blocking a substance (Angiotensin II) in the body that normally causes blood vessels to tighten. This mechanism distinguishes it from other common blood pressure medications, such as ACE inhibitors or beta-blockers.

Q: Are there any foods or drinks I should completely avoid while on Olpress?

A: According to official product information, there are no known interactions between the active ingredient in Olpress and common foods or drinks. However, regulatory documents caution that consuming alcohol may increase the risk of dizziness and may cause blood pressure to fall.

Q: Is it normal to feel dizzy or tired when starting Olpress?

A: Yes, feeling dizzy is one of the most frequently reported adverse reactions, according to regulatory documents. Fatigue and unusual tiredness or weakness are also listed among the common side effects that people may experience when starting this medicine.

Q: Can Olpress be taken at night instead of in the morning?

A: Olpress is prescribed to be taken once a day. Official product information suggests taking the dose at about the same time each day to help maintain consistency. The time of day, whether in the morning or at night, is generally flexible.

Q: How long do I usually have to take Olpress for blood pressure control?

A: Regulatory documents clarify that Olpress is used to control high blood pressure, not to cure the condition. For this reason, treatment is typically viewed as a long-term commitment to help maintain healthy blood pressure levels over time.

Q: Are there any vitamins or supplements that interact with Olpress?

A: Official warnings emphasize that Olpress can cause an increase in potassium levels and caution must be exercised with potassium supplements. It is important that healthcare providers are informed about all over-the-counter medicines, vitamins, minerals, and herbal products being taken.

Q: Are there long-term health risks associated with taking Olpress?

A: The official label includes a warning about a rare but serious long-term side effect called sprue-like enteropathy. This condition is a severe, chronic diarrheal illness with substantial weight loss that can develop months to years after beginning treatment.

Q: Can I drink alcohol moderately while taking Olpress?

A: Official warnings state that consuming alcohol can increase the risk of dizziness and may cause blood pressure to fall too low. Patients who consume alcohol should be aware of this potential effect.

Q: Does Olpress cause any skin reactions or rash?

A: Official product information lists uncommon skin reactions, including a general rash and hives (urticaria). A rare but serious allergic reaction called angioedema, which involves swelling of the face, lips, and throat, is also reported.

Q: Is Olpress ever used to prevent heart problems?

A: While the primary official indication is to lower blood pressure, this action is associated with reducing the risk of cardiovascular events, such as stroke and heart attack, associated with long-term hypertension.

Q: How does Olpress help protect the kidneys in patients with high blood pressure?

A: The drug’s action to lower blood pressure is associated with reducing the risk of renal morbidity, which means slowing the progression of kidney disease associated with high blood pressure. This effect stems from its mechanism on blood flow and sodium regulation within the kidneys.

Q: Is there a maximum time someone can safely be on Olpress?

A: According to official information, Olpress is prescribed for the long-term management of chronic high blood pressure. It is designed for sustained use and there is no mandated maximum duration of time that a patient can safely be on the medication.

Q: Do clinical trials of Olpress show differences in effect based on age or gender?

A: Regulatory documents specify different dosing guidelines for pediatric patients and note that older adults may require a lower starting dose due to slower drug processing. Official information does not specifically highlight regulatory-notable differences in the drug’s effectiveness based on gender.

Q: Can Olpress cause swelling in the ankles or feet?

A: Official safety information states that peripheral edema, or swelling in the feet, ankles, and lower legs, is reported as a common adverse reaction by people taking Olpress.

Q: How does official prescribing information describe the safety profile of Olpress for women?

A: The official prescribing information for women focuses heavily on reproductive risks: use during the second and third trimesters of pregnancy is strictly prohibited. The drug is also not recommended during the first trimester of pregnancy or while breastfeeding.

Q: Is Olpress used for any condition other than high blood pressure?

A: The only official regulatory indication for Olpress is for the treatment of hypertension (high blood pressure) in approved patient populations.

Q: Does Olpress cause weight gain or loss?

A: Regulatory information notes that a severe, chronic side effect called sprue-like enteropathy is characterized by severe diarrhea and substantial weight loss. It is also noted that weight gain may be an indication of fluid retention related to a serious kidney problem.

Q: Does taking Olpress mean I need to cut back on salt in my diet?

A: A diet low in salt and fat is generally recommended as part of a lifestyle plan to manage high blood pressure. Furthermore, patients who are already salt-depleted are noted in official warnings to be at a higher risk of experiencing low blood pressure when starting Olpress.

Q: Is Olpress safe for older adults or seniors?

A: Older adults (seniors) are cautioned in regulatory documents because they may process Olpress more slowly, which can lead to higher levels of the drug in the body. For this reason, a lower starting dosage or modified dosing schedule may be required for this population.

Q: Is Olpress a 'water pill' (diuretic)?

A: No, Olpress itself is an Angiotensin II Receptor Blocker (ARB), which is a specific class of blood pressure medication. It is sometimes prescribed in combination with a diuretic (a 'water pill') to achieve better blood pressure control.

Q: Do I need to get blood tests while I am taking Olpress?

A: Yes, official documents recommend that patients receive periodic monitoring of their renal function (kidney function) and serum electrolytes, specifically potassium levels. This monitoring is particularly important for patients who may be susceptible to changes in these measures.

Q: Can Olpress cause a persistent cough like some other blood pressure medicines?

A: Official adverse reaction reports list cough as an uncommon side effect. Unlike some other classes of blood pressure medications, a persistent cough is not generally described as a frequent or defining characteristic of this drug (an ARB).

Q: Is it safe to drive or operate machinery while taking Olpress?

A: Because dizziness, lightheadedness, or fainting is a reported side effect, official patient counseling information advises caution. Because of this risk, activities like driving or operating hazardous machinery may need to be avoided until the patient knows how the medication affects them.

Q: What are the signs that Olpress is working for me?

A: The only verifiable sign that Olpress is working is a measured decrease in your blood pressure, as confirmed by a blood pressure monitor. High blood pressure often has no symptoms, so patients should not rely on feeling different to gauge the medication's effectiveness.

Q: Will Olpress cure my high blood pressure?

A: No, Olpress does not cure high blood pressure. The drug is used as a management tool and must be taken regularly as prescribed to effectively control and maintain the blood pressure lowering effect.

Q: Why is my doctor asking me to monitor my blood pressure at home while on Olpress?

A: Official documents specify that monitoring blood pressure is necessary to ensure the drug is effective, as the dose may be adjusted based on the blood pressure response. Furthermore, the full blood pressure reduction from Olpress can take up to eight weeks to achieve.

Q: Does Olpress interact with herbal supplements like St. John's Wort?

A: Regulatory documents advise patients to discuss all herbal products and supplements with their healthcare provider before use. While not specifically listed for Olpress, caution is generally recommended, as the drug class can be involved in complex drug interactions.

Q: Can Olpress affect my mood or cause depression?

A: Although not a common adverse reaction, official safety reports have included accounts of depressed mood associated with the use of olmesartan. Any changes in mood may warrant discussion with a healthcare provider.

Q: Does Olpress interact with grapefruit or grapefruit juice?

A: According to official regulatory warnings, no specific interaction is noted between Olpress (olmesartan medoxomil) monotherapy and the consumption of grapefruit or grapefruit juice.

Q: Can I take cold medicine or decongestants while on Olpress?

A: The official label warns of interactions with certain non-prescription drugs, such as NSAIDs. Because cold medicines and decongestants can contain ingredients that affect blood pressure, information regarding their use with cold medicines or decongestants may need to be confirmed with a healthcare provider.

Q: Will Olpress lower my heart rate?

A: Olpress is an ARB and its primary mechanism is to widen blood vessels, not to lower heart rate directly. However, official information notes that a potential symptom of an overdose or excessively low blood pressure is a slow heart rate.

How should Olpress be stored and disposed of?

How to Store and Dispose of Olpress?

Olpress (olmesartan medoxomil) tablets must be stored at Controlled Room Temperature, specifically between 20 C and 25 C (68 F and 77 F). The medication must be protected from moisture and stored in its original container.

Stability and Handling

If an oral suspension is prepared, it must be refrigerated at 2 C to 8 C (36 F to 46 F) and remains stable for a maximum of four weeks. The suspension requires thorough shaking before each use. All forms of the medication must be kept out of reach of children.

Disposal

Disposal of unused or expired Olpress must be conducted according to local regulations. The product should not be discarded via household wastewater or general trash unless specified by a regulated medicine take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Olpress found in:

A-Z Index: